A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer
Nathan A. Pennell(Cleveland Clinic), Thomas J. Lynch(Nationwide Children's Hospital), Douglas S. Ross(Albert Einstein College of Medicine), Jennifer S. Temel(Massachusetts General Hospital), Sarada Gurubhagavatula(Harvard University), Lori J. Wirth(Massachusetts General Hospital), Gilbert H. Daniels(Harvard University), Rebecca S. Heist(Massachusetts General Hospital), Tracey L. Evans(University of Pennsylvania), Robert I. Haddad(Georgetown University), John R. Clark(Harvard University), Panos Fidias(Harvard University)
Cited by 198
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
|Thyroid|2016|2.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Subclinical Thyroid Disease
|JAMA|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k